| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for ActivX Biosciences, Inc. > News item |
ActivX begins first U.S. phase 1 study for anti-diabetic drug
By E. Janene Geiss
Philadelphia, March 15 - ActivX Biosciences, Inc., a wholly owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co. Ltd., announced Wednesday the filing of an Investigational New Drug application with the Food and Drug Administration for KRP-104, a compound for the treatment of type 2 diabetes.
This is Kyorin's first independently filed IND with the FDA, according to a company news release. The U.S. phase 1 clinical trial of KRP-104 began March 3, officials said.
In May 2002, ActivX and Kyorin entered into a collaboration for the discovery and development of new drugs to treat type 2 diabetes. The research quickly led to the identification of KRP-104 for clinical development, officials said.
In December 2004, Kyorin acquired ActivX and the company now acts as Kyorin's U.S. center for drug discovery and clinical development, officials said.
KRP-104 is an orally active, dipeptidyl peptidase-IV inhibitor that lowers blood glucose levels by blocking the degradation of the hormone GLP-1, thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
"KRP-104 is entering a highly competitive area of clinical development with a number of compounds in advanced clinical stages. We believe, however, that KRP-104 has a unique pharmacological profile that will more than compensate for its later market entry," John W. Kozarich, chairman and president of ActivX and chief scientific adviser for Kyorin, said in the release.
ActivX, based in La Jolla, Calif., has drug discovery, proteomics technology and clinical development capabilities. The company applies proprietary chemical technologies and high-throughput protein analysis to the drug discovery and development process.
Kyorin is a Tokyo-based research-oriented pharmaceutical company with a focus in the areas of infectious diseases, immunology and allergic diseases and metabolic diseases.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.